Introduction: Most UK laboratories use the MDRD4 formula to estimate glomerular filtration rate (eGFR), but this may exaggerate chronic kidney disease (CKD) prevalence. In a large adult population, we examined the impact of the more accurate CKD-EPI formulae on prevalence estimates, and on secular trends in prevalence. Methods: We extracted all serum creatinine (SCr) results for adults, processed in our laboratory during two 1-year periods (2004,. To minimize the effect of acute illness, a patient's lowest SCr was used for each period. eGFR (traceable to isotope dilution mass spectrometry value) was calculated using the MDRD4 and CKD-EPI formulae. Prevalence estimates were compared, with subgroup analysis by age and sex. Results: In 2004, 102 322 patients had SCr tested (35.4% of the adult population), rising to 123 121 (42.3%) in 2009-10. The proportion tested rose with age to 86% of 85-to 89-year olds. The prevalence of CKD stages 3-5 was lower with the CKD-EPI formulae than the MDRD4 formula. The
Introduction
The Kidney Disease Outcomes Quality Initiative (KDOQI) classification of chronic kidney disease (CKD) was rapidly adopted internationally after its publication in 2002. CKD stages 3-5 are defined solely on the basis of a reduced glomerular filtration rate (GFR) present for 90 days or more, whereas stages 1 and 2 also require the presence of other markers of kidney damage such as proteinuria or haematuria 1 (Appendix 1). To allow the use of the KDOQI classification in the UK, it has been recommended that estimated GFR (eGFR) be reported routinely with serum creatinine measurements in adults. 2 Most laboratories use the Modification of Diet in Renal Disease four variable formula (MDRD4), which estimates GFR from serum creatinine, age, sex and race (if available). 3, 4 The MDRD4 formula was derived from a USA CKD cohort with a mean GFR of 40 mL/min/ 1.73m 2 , and underestimates higher GFRs. 5, 6 Some have concerns that this formula may lead to overdiagnosis of CKD, particularly in the elderly and in women. 7 The Chronic Kidney Disease Epidemiology Collaboration recently derived a series of new eGFR equations (CKD-EPI formulae) with improved accuracy at higher GFRs. 8 This study has two aims: to compare the impact of the MDRD4 and CKD-EPI formulae on estimates of CKD prevalence in a UK population, and also to examine the impact on secular trends in CKD prevalence over a 5-year period.
Methods
Participants and setting NHS Ayrshire & Arran provides healthcare for its geographically defined population in the West of Scotland, with only limited coverage by other providers at the boundaries. Biochemistry services are provided by a single laboratory in Crosshouse Hospital, Kilmarnock. We downloaded all serum creatinine results reported between 1 April 2009 and 31 March 2010. Individual patients were identified using unique community health index (CHI) numbers, which are utilized in 98% of samples received by the laboratory. Samples with no CHI number, patients below 18 years of age and those receiving renal replacement therapy (RRT) were excluded. The lowest serum creatinine for each individual was selected, to minimize the potential effects of acute illness on kidney function. For analysis of secular trends, we performed the same data extraction for the period 1 January 2004 to 31 December 2004.
eGFR was calculated using the isotope dilution mass spectrometry (IDMS) traceable versions of the MDRD4 and CKD-EPI formulae (Appendix 2). No modification was made for race as our population is relatively homogeneous (99.35% white, 0.44% Indo-Asian, 0.04% black and 0.20% other). 9 CKD stage was classified using a modified version of the KDOQI CKD classification, 10,11 with stage 3 subdivided into 3A (45-59 ml/min/1.73m 2 ) and 3B (30-44 ml/min/1.73m 2 ). Local population statistics were obtained from the General Register Office for Scotland. 12 
Laboratory assays
Serum creatinine was measured using Roche Modular reagent Jaffe method, with a mean interbatch coefficient of variation (CV) of 2.3% at a sCr concentration of 148 mmol/l and 1.7% at 326 mmol/l. In 2004, serum creatinine was measured by the O'Leary modifications of picrate method of Jaffe. The between-day CVs were <2.0% at concentrations of 100 and 485 mmol/l. Both assays were performed using Roche Modular P Units. We used the adjustment factors produced by the UK National External Quality Assessment Service for each creatinine assay, to produce IDMS-traceable serum creatinine values. 13 
Statistical analyses
Data were analysed using SPSS 16.0 for Windows (SPSS Inc, Chicago, IL, USA). Appropriate summary statistics were obtained and comparison tables constructed. Agreement between the estimated GFR predicted by each formula was assessed using the Bland-Altman method.
We compared the prevalence of CKD by age and CKD stage in our laboratory database population with that of two population-based studies (US National Health and Nutrition Examination Survey [NHANES] 1999-2006 data 8 and the Health Survey for England [HSE] ). We took the CKD prevalence based on our laboratory database (using the CKD-EPI formulae on the 2009-10 population) as the measured prevalence. We derived predicted CKD prevalence by applying the NHANES and HSE prevalences for each age band and CKD stage to our population. By assuming that any deficit in CKD prevalence between measured and predicted prevalence was due to unidentified CKD in the unbled population, we estimated what CKD prevalence would be required in the unbled proportion of our population, if our actual population prevalence was the same as NHANES or HSE.
Results
The adult population of Ayrshire and Arran in 2009 was 293 880. 12 Between April 2009 and March 2010, 438 872 serum samples were analysed for creatinine. Following removal of repeat samples on individuals, and application of the exclusion criteria, the study population was 123 121 (Figure 1 , Table 1 ). The population distribution and percentage with serum creatinine results by age band is shown in Figure 2 . Overall 42% of the adult population, and 71% of those over 65 years old had serum creatinine measured in the year.
The relationship between eGFR as estimated by the MDRD4 formula and the CKD-EPI formulae is shown in Figure 3 . The prevalence of CKD stages 3-5 fell from 13.4% of our study population when using the MDRD4 formula, to 11.8% using the CKD-EPI formulae. The impact on prevalence by CKD stage, age and gender is shown in Tables 2  and 3 . The difference between eGFR as estimated by the different formulae in relation to age is shown in Figure 4 .
As our laboratory database estimates of CKD prevalence are lower than those produced by population survey studies (Table 4) , we calculated the prevalence estimates by age and CKD stage that would be necessary in our unbled population, if the CKD prevalence in our total population was to match the prevalence estimates from the NHANES and HSE populations.
Comparison of 2004 and 2009-10 cohorts
The characteristics of the 2004 cohort are shown in Table 1 . The proportion bled by age group has been published previously.
14 From 2004 to 2009-10, the number of serum samples analysed for creatinine in our laboratory has increased by 28% from 341 928 to 438 872. The total adult population has grown by 0.5%, whereas the number of individual adults having their serum creatinine measured increased by 20% from 102 322 to 123 121. The change in prevalence of CKD between the two-time periods is shown in Table 5 , according to MDRD4 and CKD-EPI formulae.
Discussion
Our study shows that changing from the MDRD4 formula to the CKD-EPI formulae to measure eGFR in a UK population, would result in a small reduction in the overall prevalence of CKD stage 3-5 by 0.69% (from 5.63% to 4.94%), with most of these patients reclassified to eGFR >60 ml/min/1.73m 2 . There is relatively little reclassification of CKD stage seen with more severe kidney disease. The 170 14 (5.8% of the adult population) patients reclassified to milder stages of CKD are mainly female (67%) with a mean age of 50 AE 12.2 years. Additionally, we found that the CKD-EPI formulae reclassified 5172 (1.8%) patients to more severe CKD stages, mostly affecting elderly females (mean age 81.5 AE 6.6 years). Kidney function was assessed in a remarkably large proportion of the adult population with 42% assessed in 2009-10 (compared to 35% in 2004), rising to a peak of 86% in those aged 85-89 years. Of note, there was no rise in population CKD prevalence between 2004 and 2009-10 when eGFR was assessed by the CKD-EPI formulae, and only a small rise of 0.2% when using the MDRD4 formula, despite the 20% increase in the proportion of the population being assessed.
The CKD-EPI formulae were derived in 5504 subjects from 10 studies with formal GFR measures performed. The formulae were validated in 2750 additional subjects from the same studies, and also against an external set of 3896 subjects from 16 other studies. The mean GFR from the combined populations was 68 ml/min/1.73m 2 , 44% were female, 71% were white and the mean age was 48 years. The CKD-EPI formulae in these studies estimated GFR as accurately as the MDRD4 formula in subjects with eGFR <60 ml/min/1.73m 2 , but was more accurate at higher levels of eGFR. Precision remained relatively poor.
Levey and colleagues assessed the impact of the different formulae on CKD prevalence, using the NHANES 1999-2006 population. 8 They found a rise in mean eGFR of 6.9 ml/min/1.73m 2 , and a fall of 1.5% in prevalence of stage 3 CKD when the CKD-EPI formulae were used. Women and those aged 20-69 years had a disproportionate reduction in prevalence of CKD. An Italian study of 38 188 patients calculated eGFR using both formulae. 15 The estimated prevalence of CKD fell by 1.6% using the CKD-EPI formulae, with a significant drop in the prevalence of stage 2 disease (15.3%). In a cohort of 14 427 Spanish patients, the mean eGFR was 0.6 ml/min/1.73m 2 higher with CKD-EPI as compared to MDRD4, and CKD-EPI led to reclassification of patients to lower stages of CKD, particularly affecting stages 2, 3A and 3B, women and Figure 3 . Bland-Altman plot of eGFR calculated using the CKD-EPI formulae and the MDRD4 study formula. The bold diagonal rows are patients whose GFR group does not change depending on which eGFR formula is used. The top diagonal row represents patients reclassified to a higher GFR group when using the CKD-EPI formulae, whereas the bottom diagonal row represents patients reclassified to a lower GFR group by the CKD-EPI formulae. Percentages of the study population (i.e. those patients with blood samples taken during the study year) are shown for each CKD stage by eGFR formula.
F; female.
those <70 years old. In keeping with our study, they found some reclassification of older females to higher CKD stages with CKD-EPI. 16 Similarly, a Dutch population based cross-sectional survey of 6097 participants concluded that the CKD-EPI formulae provide higher estimates of GFR than the MDRD4 formula. However, women >75 and men >70 years had lower median eGFR values.
17 A Belgian screening study of 1992 volunteers aged between 45-and 84-years old showed mean eGFR to be 2 ml/min/1.73m 2 higher with CKD-EPI, and prevalence of CKD stage 3 fell from 11.04 to 7.98%, with greater impact in women. 18 In comparison to these studies, we found a relatively small change in eGFR and CKD prevalence when using the CKD-EPI formulae. This is at least in part because our population is substantially older, and the reduction in CKD amongst adults under 70-years old is partially offset by the increased prevalence amongst the elderly, as could be predicted from Figure 4 . Of note, only 0.6% of the CKD-EPI population were >80-years old, and only 5.3% over 70 years old. A recent large UK primary care study found an overall reduction in CKD prevalence of 0.61% using the CKD-EPI equation; however, fluctuation in serum creatinine measurements accounted for a greater proportion of the change in prevalence, than the different formulae. 19 
Figure 4.
Relationship between age and the difference in eGFR calculated using the CKD-EPI formulae and the MDRD4 study formula. Our study has a number of limitations. There was no formal GFR measurement performed to allow direct comparison with the prediction formulae. The serum creatinine assay changed between the two study periods but both were converted to the IDMS-traceable serum creatinine value before the eGFR was calculated, thereby minimising bias. We defined patients as having CKD on the basis of a single eGFR, rather than two samples >90 days apart, 19 but we minimized the impact of this by using the lowest serum creatinine available for each patient in the study year. Nevertheless, we may have over-diagnosed CKD in some patients. The strength of our study is its size, its use of all laboratory samples performed in a geographically defined population and that the population is clinically relevant.
Our study cohort comprised patients who have had kidney function assessed for a clinical indication, raising the possibility of selection bias. One would expect the unbled population to have low comorbidity and thus a low prevalence of CKD. Nevertheless, to ascertain true population prevalence would require a population survey. To explore this further, we calculated the prevalence that would be required in our unbled population, if our total population CKD prevalence were comparable to the NHANES population (adjusting for our older population). Using this approach, the CKD prevalence in the unbled population >60-years old would need to be higher than in the bled population (Table 5) . Whereas there will be some unidentified CKD, it seems unlikely to be more prevalent than in the bled population. Compared to the NHANES population, our population has a slightly higher proportion of females, and a far higher proportion of whites, both of which should lead to higher rather than lower CKD prevalence. Furthermore, NHANES excluded adults living in institutions, who have a high prevalence of CKD, 20 whereas our data include such patients. It therefore seems likely that our population has a genuinely lower prevalence of CKD than in the USA. Previous estimates of the prevalence of kidney disease in the UK have varied substantially. 21 Despite the different methodological approach of the Health Survey for UK, and allowing for their relatively small sample size (n = 2171), our CKD prevalence rates are similar. 22 This suggests that age-adjusted CKD prevalence is genuinely lower in the UK than in the USA. Larger population-based surveys of CKD prevalence would be warranted in the UK to give more precise estimates of prevalence over time.
Two studies have assessed clinical outcomes in patients who have been reclassified by the CKD-EPI formulae. The AUSDIAB study compared outcomes in three categories of patients: those with CKD by both equations, those with CKD only by MDRD4 and those without CKD by either formula. 23 In keeping with our study, they found that those reclassified were mainly women. They found no evidence of increased all-cause mortality in the reclassified group, suggesting that they are low-risk individuals. A similar post hoc analysis of the ARIC study 24 found reclassified individuals were more likely to be female, middle-aged and white. Moreover, the reclassification of this sub-group was more appropriate with regard to their comparable risk of unfavourable outcomes such as end-stage renal disease, all cause mortality, coronary heart disease and stroke. There are no outcome studies from the UK. In our study population, 1.8% of subjects were reclassified to higher stages of CKD-no patients in ARIC and few in AUSDIAB were reclassified in this way. It will be of importance to examine outcomes in this group before the equation is implemented in clinical laboratories.
In practical terms, the implementation of the routine use of eGFR CKD-EPI formulae in place of the MDRD4 formula in the UK would result in fewer people being identified as suffering from CKD, without apparent increased risk to those reclassified to milder disease (though this should be confirmed in a UK population). The resultant fall in the number undergoing routine monitoring may result in reduced medicalization of patients, and reduce the financial burden and workload in primary care. However, a large proportion of those on primary care CKD registers also suffer from hypertension, vascular disease and/or diabetes mellitus and would continue to receive similar monitoring as a result of these other conditions. The magnitude of any potential saving would have to be directly assessed. Implementation costs would be low, as it requires no change to instrumentation or assays.
In conclusion, measurement of eGFR using the CKD-EPI equation reduced the overall prevalence of CKD, in particular stage 3A, in a predominantly Caucasian general population cohort. This was particularly prominent in females and those middle-aged. Using the MDRD4 formula, there is an apparent minor rise in CKD prevalence over the study time period, but this is not seen when using the CKD-EPI formulae. The CKD-EPI formulae may reduce overdiagnosis of CKD, but further assessment in the elderly is required before widespread implementation. Sex Impact of MDRD and CKD-EPI formulae
